Clinical trials
Phase 2/3 trials in the Philippines
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Terminated | 6 |
| Active, not recruiting | 4 |
| Unknown status | 4 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 4 |
| Boehringer Ingelheim | 2 |
| Bristol-Myers Squibb | 2 |
| LG Chem | 2 |
| Algernon Pharmaceuticals | 1 |
| Anthera Pharmaceuticals | 1 |
| AstraZeneca | 1 |
| Biogen | 1 |
| CSL Behring | 1 |
| Clover Biopharmaceuticals AUS Pty | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 9 |
| Glomerulonephritis, IGA | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Poliomyelitis | 2 |
| Stomach Neoplasms | 2 |
| Tuberculosis, Pulmonary | 2 |
| Arthritis, Rheumatoid | 1 |
| Asthma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Transitional Cell | 1 |
Trials
Showing 76 to 44 of 44. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.